2012
Glycolipid Antigens for Treating Hepatic Colorectal Cancer Metastases and Their Effect on the Therapeutic Efficacy of Live Attenuated Listeria monocytogenes
Olino K, Edil BH, Meckel KF, Pan X, Thuluvath A, Pardoll DM, Schulick RD, Yoshimura K, Weber WP. Glycolipid Antigens for Treating Hepatic Colorectal Cancer Metastases and Their Effect on the Therapeutic Efficacy of Live Attenuated Listeria monocytogenes. JAMA Surgery 2012, 147: 480-482. PMID: 22785644, PMCID: PMC4144826, DOI: 10.1001/archsurg.2011.2206.Peer-Reviewed Original ResearchConceptsNatural killer T cellsHepatic colorectal cancer metastasesKiller T cellsColorectal cancer metastasisT cellsNatural Killer T Cell SubsetsCancer metastasisAntitumor activityT cell subsetsAttenuated Listeria monocytogenesPotential of glycolipidsTumor challengeHepatic metastasesMultiple administrationsGlycolipid antigensTherapeutic efficacyListeria monocytogenesActin AAntitumor efficacyMetastasisFurther investigationAdministrationEfficacySpecific glycolipidsSurvival
2010
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare